FDA draft MDUFA VI flags AI

The Food and Drug Administration’s draft MDUFA VI commitment letter is not an AI rulebook, but it does show where device regulation is heading. The Bipartisan Policy Center said in an August 4 analysis that the draft points to a review system preparing for software-defined products, including AI-enabled tools and digital health platforms. (bipartisanpolicy.org) The letter covers the next round of the Medical Device User Fee Amendments, the program under which device makers pay fees and FDA commits to review timelines and other performance goals. The current MDUFA V program expires on September 30, 2027, and the draft now under discussion would govern fiscal years 2028 through 2032. ### Why does a user-fee letter matter for AI at all? (fda.gov) The MDUFA program sets the operating terms for FDA’s device review system, not just the fee schedule. FDA says MDUFA VI includes public meetings, stakeholder consultations and a draft commitment letter laying out “performance goals and procedures” for fiscal years 2028 through 2032. Bipartisan Policy Center said that makes the document an early signal of how the agency wants to handle emerging device categories, including AI and digital health products. August 4 was the date of the Bipartisan Policy Center analysis, written by Allison Kwon and Maya Sandalow. The group said the draft letter “foreshadows the agency’s vision for overseeing medical devices” and offers industry chances to participate in “innovative regulatory approaches, including pilots and sandboxes,” while also emphasizing internal reviewer expertise for generative and agentic AI. (bipartisanpolicy.org) ### Which parts of the draft point most directly to software-defined devices? FDA-industry negotiations earlier this year included digital health among the topics advanced into draft commitment-letter language. Minutes from a February 18, 2026 FDA-industry reauthorization meeting said FDA and industry had agreed to move forward with drafting language for “Patient Science, Digital Health, Third Party 510(k) Review Program.” (fda.gov) The Bipartisan Policy Center said the draft suggests FDA is building capacity around products that depend on software, data flows and iterative models rather than fixed hardware alone. That matters for companies working on imaging software, AI triage systems, cloud-based diagnostics and digital surgical platforms, all of which can fall under medical-device oversight depending on their intended use. (bipartisanpolicy.org) ### What does this mean for ophthalmology companies? Ophthalmology is heavily exposed to software-based regulation because many of its tools already sit at the intersection of imaging, diagnostics and workflow software. Retinal image analysis, glaucoma progression tools, cloud-connected diagnostics and operating-room visualization systems are examples of products that could face evolving review expectations if FDA expands expertise and pilot programs around AI-enabled devices, according to the Bipartisan Policy Center analysis. (fda.gov) FDA has not issued an ophthalmology-specific policy in the draft MDUFA VI materials now posted online. But the agency’s MDUFA VI page and reauthorization records show a process that is already incorporating digital health into the broader structure of the next device-review cycle. (bipartisanpolicy.org) ### What happens next in the MDUFA VI process? July 7 was the date FDA posted the draft MDUFA VI commitment letter, according to the Bipartisan Policy Center analysis. FDA must finalize the letter and send Congress its recommended user-fee revenues and performance goals by January 15, 2027, the policy group said. The current MDUFA V authority then runs until September 30, 2027. (bipartisanpolicy.org) August 5, 2026 is listed on FDA’s MDUFA VI webpage as a public meeting date. That page also includes the draft commitment letter and records from stakeholder and industry consultations that will feed into the final package sent to Congress. (bipartisanpolicy.org) (fda.gov)